Watch the presentations from the UK Cystic Fibrosis Conference.
In this section
07 September 2017
Welcome and conference introduction from George Jenkins, Chair of Trustees at the Cystic Fibrosis Trust, and David Ramsden, CEO at the Trust.
'Understanding how CFTR keeps the lungs healthy and what to do about it when it doesn’t work' – David Sheppard, Professor of Physiology at the University of Bristol, followed by 'The importance of Airway Surface Liquid (ASL) interface, volume and pH' - Robert Tarran, Associate Professor of Cell Biology and Physiology at the University of North Carolina.
Visualising the cilia - Dr Pietro Cicuta, Head of Biological and Soft Systems at Cavendish Laboratory, University of Cambridge.
Targeting non-CFTR ion channels that could offer opportunities for new CF therapies - Dr Michael Gray, Cellular Physiology, University of Newcastle
Targeting other channels involved in ASL and using bronchospheres to screen for compounds that influence ASL - Dr Henry Danahay, Head of Biology at Enterprise Therapeutics.
Introductory chair scene setting (five minutes) by David Thornton, Professor of Biochemistry, University of Manchester, followed by Anna Ermund, Medical Biochemistry and Cell Biology at the University of Gothernburg, presenting on how ion channel dysfunction affects mucus in the lung.
‘Hot off the press’ - OligoG: A novel approach to treating mucus dysfunction, Phase 2b results and plans for the future - Astrid Hilde Myrset, Director for Pre-Clinical and Clinical Research at AlgiPharma.
Pulmonary infection by Pseudomonas aeruginosa and the case for new antimicrobials - Jane Davies, Professor in Paediatric Respirology, Imperial College London and Royal Brompton Hospital.
Review on Antimicrobial Resistance and addressing the global economic challenges of developing new antibiotics – William Hall, previously Senior Policy Adviser on the Review into Antimicrobial Resistance.
A novel therapeutic approach to resolve inflammation in CF and results from a Phase 2 study - Barbara White, MD Chief Medical Officer at Corbus Pharmaceuticals, Inc.
Correcting CFTR, long-term follow up data on the use of ivacaftor - Stuart Elborn, Professor of Respiratory Medicine, Imperial College London and Royal Brompton Hospital.
Clinical trials: where are we now? - Dr Damian Downey, Consultant Respiratory Physician at Queens University Belfast.
Keynote - The role of the Trials Development Network in coordinating CF trials in the USA, the increased number of trials and finding better outcome measures that reflect patient need - George Retsch-Bogart, University of North Carolina and Cystic Fibrosis Foundation Trials Development Network.
Increasing capacity for clinical trials in the UK through the Clinical Trials Accelerator Platform - Keith Brownlee, Director of Impact at the Cystic Fibrosis Trust.
Forum - What are the experiences of people who have taken part in cystic fibrosis clinical trials? - Katie Gathercole and Zoe Elliott.
The challenges of clinical trials in the age of personalised medicine, an industry perspective - David Geller, Medical Director CF at Abbvie.
A year in the life of the Cystic Fibrosis Trust - meet the CEO, with updates on the UK CF Registry, research, fundraising, policy, volunteering and future plans - Oli Lewington, Director of Engagement, and David Ramsden, Chief Executive.
Sponsor Lunchtime Symposium - ‘Beyond the Lung’ - Vertex
Workshop A: clinical psychology – the science of psychology and the thriving child and adolescent - Dr James Lemon, Consultant Clinical Psychologist, NHS
Workshop B: Nutrition - practical ways of monitoring nutritional status in cystic fibrosis - Darren Sills, Lead Adult Cystic Fibrosis Dietician, Wolfson Adult CF Unit, Nottingham University Hospital Trust
Workshop C: Physiotherapy - clinical exercise testing and prescription - Professor Craig Williams, Director at the Children’s Health and Exercise Research Centre, University of Exeter
Workshop D: Pharmacy - access to new medicines, pipelines to patients - Patrick Wilson, Assistant Head of Pharmacy at Clinical and Operational Services Pharmacy Department, Nottingham University Hospitals
12 September 2017
Roger Black hosts our competition for early career researchers in cystic fibrosis to present their work to a lay audience. Watch all of the presentations and find out who this year's winner is!
Hear from cystic fibrosis Clinical Nurse Specialist Jacqui Cowlard on just exactly what cross-infection means to people with CF and their friends and families.
F508del? W1282X? We explain the different CF-causing mutations of the gene that makes the CFTR protein, and why drugs like Orkambi and Kalydeco work.
We spoke to kids with cystic fibrosis to find out what their CF means to them - check out their answers!
So what is CF, exactly? Youtuber Charles Michael Duke breaks it down!
We fund research to tackle some of the most pressing issues in CF today. Find out how your donations are making a difference.
Cystic fibrosis, or CF, affects the lungs, digestive system and other organs, and there are around 10,500 people living with it in the UK.
Get in touch with us to speak to someone on our Helpline, find out about an event or speak to our Press Team.